Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tharimmune Inc (THAR)

Tharimmune Inc (THAR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,358
  • Shares Outstanding, K 1,486
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,320 K
  • EBIT $ -11 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.86

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.85 +12.43%
on 11/18/24
6.39 -67.45%
on 10/30/24
+0.05 (+2.46%)
since 10/29/24
3-Month
1.84 +13.35%
on 10/07/24
6.39 -67.45%
on 10/30/24
-0.72 (-25.65%)
since 08/29/24
52-Week
1.84 +13.35%
on 10/07/24
14.09 -85.23%
on 11/30/23
-12.29 (-85.53%)
since 11/29/23

Most Recent Stories

More News
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City,...

THAR : 2.08 (-7.96%)
ACXP : 1.2500 (+9.17%)
UBI.AX : 0.130 (+8.33%)
GRF.VN : 0.530 (-3.64%)
WISA : 1.6400 (+1.23%)
NNVC : 1.3600 (-1.45%)
ALCO : 26.80 (+0.53%)
MYPS : 1.9200 (+3.78%)
ABL : 8.18 (+1.24%)
PERF : 2.6100 (+36.65%)
PETV : 0.4725 (-5.50%)
ABEO : 6.39 (-0.31%)
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City,...

ESGH.TO : 29.14 (-1.15%)
THAR : 2.08 (-7.96%)
ACXP : 1.2500 (+9.17%)
GRF.VN : 0.530 (-3.64%)
WISA : 1.6400 (+1.23%)
ALCO : 26.80 (+0.53%)
NNVC : 1.3600 (-1.45%)
ABL : 8.18 (+1.24%)
MYPS : 1.9200 (+3.78%)
PERF : 2.6100 (+36.65%)
PETV : 0.4725 (-5.50%)
ABEO : 6.39 (-0.31%)
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing safety profile

THAR : 2.08 (-7.96%)
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

FDA Provides Positive Feedback to Company Regarding TH104 Phase 2 Program

THAR : 2.08 (-7.96%)
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

FDA Provides Positive Feedback to Company Regarding TH104 Phase 2 Program

THAR : 2.08 (-7.96%)
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Phase 1 ex-US trial in chronic liver disease patients in an open-label study showed a 33.3% decrease in 24-hour mean itching intensity score after a single dose

THAR : 2.08 (-7.96%)
Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

BRIDGEWATER, NJ / ACCESSWIRE / November 27, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates...

THAR : 2.08 (-7.96%)

Business Summary

Tharimmune Inc. is a biotechnology company. It involved in developing a portfolio of therapeutic candidates for rare immune, inflammatory and oncologic diseases. Tharimmune Inc., formerly known as Hillstream BioPharma Inc., is based in BRIDGEWATER, NJ.

See More

Key Turning Points

3rd Resistance Point 2.46
2nd Resistance Point 2.36
1st Resistance Point 2.22
Last Price 2.08
1st Support Level 1.98
2nd Support Level 1.88
3rd Support Level 1.74

See More

52-Week High 14.09
Fibonacci 61.8% 9.41
Fibonacci 50% 7.96
Fibonacci 38.2% 6.51
Last Price 2.08
52-Week Low 1.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar